Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Partner to Advance Groundbreaking ALS Therapy

- Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying patholo...

December 05, 2024 | Thursday | News
Merck’s Sacituzumab Tirumotecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthroug...

December 04, 2024 | Wednesday | News
Inari Medical Receives National Reimbursement Approval for ClotTriever Thrombectomy System in Japan

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering fr...

December 03, 2024 | Tuesday | News
Deepull Secures FDA Breakthrough Device Designation for Transformative Bloodstream Infection Test

deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification, announced that it has receive...

December 02, 2024 | Monday | News
Taiwan’s Formosa Pharmaceuticals Partners with Medvisis to Launch Innovative Ophthalmic Treatment in Switzerland and Liechtenstein

Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Medvisis Switze...

November 29, 2024 | Friday | News
Novartis Announces European Commission Approval of Kisqali® (ribociclib) for Adjuvant Treatment of High-Risk HR+/HER2- Early Breast Cancer

Novartis announced that the European Commission (EC) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the ad...

November 28, 2024 | Thursday | News
Alnylam's Vutrisiran sNDA Accepted by FDA for Priority Review in ATTR-CM with March 2025 Decision Expected

 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration&n...

November 26, 2024 | Tuesday | News
GSK’s Blenrep Combination Therapy Accepted for FDA Review in Relapsed Multiple Myeloma

GSK plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for Blenrep&...

November 26, 2024 | Tuesday | News
MSD Announces Positive Phase 3 ZENITH Study Results for WINREVAIR in Pulmonary Arterial Hypertension

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced positive topline results from the Phase 3 ZENITH study evaluating WINREV...

November 26, 2024 | Tuesday | News
West China Lecheng Hospital Launches Vorasidenib, First-in-Class Targeted Therapy for IDH-Mutant Glioma

It was announced that West China Lecheng Hospital has successfully introduced Vorasidenib for treatment at clinical practices, and the treatment began at o...

November 25, 2024 | Monday | News
Hanmi Pharmaceutical Showcases Promising Clinical Progress of BH3120 at SITC 2024 Conference

The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical...

November 25, 2024 | Monday | News
Zevra Therapeutics Launches MIPLYFFA™, the First FDA-Approved Treatment for Niemann-Pick Disease Type C

MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra’s specialty pharmacy for dispense AmplifyAssist&...

November 22, 2024 | Friday | News
Kedrion Biopharma's Bolognana Facility FDA-Approved to Manufacture RYPLAZIM® for PLGD-1 Treatment

 Kedrion Biopharma Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the company's manufacturing facility in B...

November 22, 2024 | Friday | News
Jazz Pharmaceuticals Secures FDA Approval for Ziihera, First Dual HER2-Targeted Therapy for Advanced Biliary Tract Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera® (zan...

November 21, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close